Naltrexone protects against lipopolysaccharide/D-galactosamine-induced hepatitis in mice

Journal of Pharmacological Sciences

Volumn 108, Issue 3, 2008, Pages 239-247

  Wang, Chien Chuan ^a,f   Cheng, Pao Yun ^b   Peng, Yie Jen ^c,f   Wu, Edwin S C ^d   Wei, Hsiao Ping ^e   Yen, Mao Hsiung ^f  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d Jenken Biosciences Inc   (United States)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

D galactosamine; Lipopolysaccharide; Naltrexone; Nitric oxide; Tumor necrosis factor

Indexed keywords

GALACTOSAMINE; LIPOPOLYSACCHARIDE; NALTREXONE; NITRIC OXIDE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEPATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; LIVER FUNCTION; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; TREATMENT RESPONSE;

EID: 56649109909     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08096FP     Document Type: Article

References (48)

1. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury. J Gastroenterol Hepatol. 2000;15:718-724.
2. Jaeschke H, Farhood A, Smith CW. Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent echanism. Am J Physiol. 1991;261:G1051-G1056.
3. Hewett JA, Schultze AE, Vancise S, Roth RA. Neutrophil depletion protects against liver injury from bacterial endotoxin. Lab Invest. 1992;66:347-361.
4. Dohi F, Goya T, Torisu M. Potential role of hepatic macrophages in neutrophil-mediated liver injury in rats with sepsis. Hepatology. 1993;17:1086-1094.
5. McCuskey RS, Nishida J, Euchi H, McDonnell D, Baker GL, Ekataksin W, et al. Role of endotoxin in the hepatic microvascular response to ethanol. J Gastroenterol Hepatol. 1995;10:S18-S23.
6. Bautista AP. Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein-2 production and intercellular adhesion molecule-1 expression in the liver. Hepatology. 1997;25:335-342.
7. Essani NA, Fisher MA, Farhood A, Manning AM, Smith CW, Jaeschke H. Cytokine-induced hepatic intercellular adhesion molecule-1 (ICAM-1) mRNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure. Hepatology. 1995;21:1632-1639.
8. Essani NA, Bajt ML, Vonderfecht SL, Farhood A, Jaeschke H. Transcriptional activation of vascular cell adhesion molecule-1 (VCAM-1) gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Immunol. 1997;158:5941-5948.
9. Chosay JG, Essani NA, Dunn CJ, Jaeschke H. Neutrophil margination and extravasation in sinusoids and venules of the liver during endotoxininduced injury. Am J Physiol. 1997;272:G1195-G1200.
10. Maroushek-Boury N, Czuprynski CJ. Listeria monocytogenes infection increases neutrophil adhesion and damage to a murine hepatocyte cell line in vitro. Immunol Lett. 1995;46:111-116.
11. Nagendra AR, Mickelson JK, Smith CW. CD18 integrin and intercellular adhesion molecule-1 (CD54)-dependent neutrophil adhesion to cytokinestimulated human hepatocytes. Am J Physiol. 1997;272:G408-G416.
12. Jaeschke H, Ho YS, Fisher MA, Lawson JA, Farhood A. Glutathione peroxidase-deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of an intracellular oxidant stress. Hepatology. 1999;29:443-450.
13. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A. 1979;76: 5939-5943.
14. Admason GM, Billings RE. Tumor necrosis factor induced oxidative stress in isolated mouse hepatocytes. Arch Biochem Biophys. 1992;294:223-229.
15. Greeneltch KM, Haudenschild CC, Keegan AD, Shi Y. The opoid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-α production. Brain Behav Immun. 2004;18:476-484.
16. Song Z, Joshi-Barve S, Barve S, McClain CJ. Advances in alcoholic liver disease. Current Gastroenterology Reports. 2004;6:71-76.
17. McClain CJ, Song Z, Barve S, Hill DB, Deaciuc I. Recent Advances in Alcoholic Liver Disease IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physio Gastrointest Liver Physiol. 2004;287:G497-G502.
18. Lin SL, Lee YM, Chang HY, Cheng YW, Yen MH. Effects of naltrexone on lipopolysaccaride-induced sepsis in rats. J Biomed Sci. 2005;12:431-440.
19. Ray A, Mediratta PK, Sen P. Modulation by naltrexone of stress-induced changes in humoral immune responsiveness and gastric mucosal integrity in rats. Physiol Behav. 1992;51:293-296.
20. Hong HJ, Loh SH, Yen MH. Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br J Pharmacol. 2000;131:631-637.
21. Wang CC, Lee YM, Wei HP, Yen MH. Dextromethorphan prevents circulatory failure in rats with endotoxemia. J Biomed Sci. 2004;11:739-747.
22. Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL. Effects of long term therapy with naltrexone on body weight in obesity. Clin Pharm Ther. 1985;384:19-22.
23. Malcolm R, O'Neil PM, Sexauer JD, Riddle FE, Currey HS, Counts C. A controlled trial of naltrexone in obese humans. Int J Obes. 1985;9:347-353.
24. Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, et al. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986;67:66-72.
25. Mosby's Drug Consult (2005). Naltrexone Hydrochloride (001857). Copyright Mosby, Inc. MDconsult. http://home.mdconsult.com.
26. Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol. 1994;34:898-901.
27. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130-1135.
28. Brewer C, Wong VS. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol. 2004;9:81-87.
29. Grant JE. Outcome study of kleptomania patients treated with naltrexone: a chart review. Clin Neuropharmacol. 2005;28:11-14.
30. Brahen LS, Capone TJ, Capone DM. Naltrexone: lack of effect on hepatic enzymes. J Clin Pharmacol. 1988;2:64-70.
31. Yen MH, Ko HC, Tang FI, Lu RB, Hong JS. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol. 2006;38:117-120.
32. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798-802.
33. Li G, Liu Y, Tzeng NS, Cui G, Block ML, Wilson B, et al. Protective effect of dextromethorphan against endotoxin shock in mice. Biochem Pharmacol. 2005;69:233-240.
34. Hishinuma I, Nagakawa J, Hirota K, Miyamoto K, Tsukidate K, Yamanaka T, et al. Involvement of tumor necrosis factor-alpha in development of hepatic injury in galactosamine-sensitized mice. Hepatology. 1990;12:1187-1191.
35. Lehmann V, Freudenberg MA, Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine- treated mice. J Exp Med. 1987;165:657-663.
36. Liu J, Saavedra JE, Lu T, Song JG, Clark J, Waalkes MP, et al. O(2)- Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate protection against D-galactosamine/endotoxin-induced hepatotoxicity in mice: genomic analysis using microarrays. J Pharmacol Exp Ther. 2002;300:18-25.
37. Hewett JA, Roth RA. Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharides. Pharmacol Rev. 1993;45:382-411.
38. Enomoto N, Takei Y, Hirose M, Kitamura T, Ikejima K, Sato N. Protective effect of thalidomide on endotoxin-induced liver injury. Alcohol Clin Exp Res. 2003;27:2S-6S.
39. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci. 2002;65:166-176.
40. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol. 1995;154:1307-1316.
41. Schlayer HJ, Laaff H, Peters T, Woort-Menker M, Estler HC, Karck U, et al. Involvement of tumor necrosis factor in endotoxin-triggered neutrophil adherence to sinusoidal endothelial cells of mouse liver and its modulation in acute phase. J Hepatol. 1988;7:239-249.
42. Essani NA, Fisher MA, Farhood A, Manning AM, Smith CW, Jaeschke H. Cytokine-induced upregulation of hepatic intercellular adhesion molecule-1 messenger RNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure. Hepatology. 1995;21:1632-1639.
43. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997;112:321S-329S.
44. Horn KD. Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS). QJM. 1998;1:265-277.
45. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620-1624.
46. Kukreja RC, Hess ML. The oxygen free radical system: From equations through membraneprotein interactions to cardiovascular injury and protection. Cardiovasc Res. 1992;26:641-655.
47. Lysle DT, How T. Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes. J Pharmacol Exp Ther. 1999;288:502-508.
48. Jaume M, Jacquet S, Cavaillès P, Gaëtane M, Stephan L, Blanpied C. Opioid receptor blockage reduces Fas-induced hepatitis in mice. Hepatology. 2004;40:1136-1143.